Scarica l'app Stockscreener
141.69
2.27%
-3.29
Dopo l'orario di chiusura:
142.50
0.81
+0.57%
Precedente Chiudi:
$144.98
Aprire:
$145.215
Volume 24 ore:
1.42M
Relative Volume:
1.79
Capitalizzazione di mercato:
$6.85B
Reddito:
-
Utile/perdita netta:
$-177.04M
Rapporto P/E:
-37.42
EPS:
-3.7867
Flusso di cassa netto:
$-153.53M
1 W Prestazione:
+18.01%
1M Prestazione:
+25.80%
6M Prestazione:
+89.96%
1 anno Prestazione:
+1,206%
Intervallo 1D:
$139.31
$147.33
Intervallo di 1 settimana:
$116.50
$151.02
Portata 52W:
$9.51
$151.02
Celcuity Inc Stock (CELC) Company Profile
Nome
Celcuity Inc
Settore
Industria
Telefono
763-392-0767
Indirizzo
16305 36TH AVENUE N, MINNEAPOLIS, MN
Compare CELC vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CELC
Celcuity Inc
|
141.69 | 7.01B | 0 | -177.04M | -153.53M | -3.7867 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Celcuity Inc Stock (CELC) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-27 | Iniziato | Citizens | Mkt Outperform |
| 2025-12-12 | Iniziato | Wells Fargo | Overweight |
| 2025-11-18 | Iniziato | Wolfe Research | Outperform |
| 2025-11-17 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2025-09-22 | Iniziato | Guggenheim | Buy |
| 2025-07-01 | Ripresa | Stifel | Buy |
| 2024-07-22 | Iniziato | Leerink Partners | Outperform |
| 2024-02-22 | Iniziato | Stifel | Buy |
| 2023-12-08 | Iniziato | H.C. Wainwright | Buy |
| 2021-10-08 | Iniziato | Canaccord Genuity | Buy |
| 2021-09-07 | Iniziato | Jefferies | Buy |
| 2021-07-29 | Iniziato | Cowen | Outperform |
| 2021-07-27 | Iniziato | Needham | Buy |
| 2021-01-28 | Reiterato | H.C. Wainwright | Buy |
| 2020-12-24 | Reiterato | H.C. Wainwright | Buy |
| 2020-05-11 | Ripresa | Craig Hallum | Buy |
| 2018-11-20 | Iniziato | H.C. Wainwright | Buy |
Mostra tutto
Celcuity Inc Borsa (CELC) Ultime notizie
Is It Too Late To Consider Celcuity (CELC) After A 13x One Year Surge? - Yahoo Finance
ASCO 2026 preview – Celcuity gets a mutant coup | ApexOncoClinical Trials news and analysis - Oncology Pipeline
Celcuity reports Phase III VIKTORIA-1 trial results for breast cancer - Clinical Trials Arena
Celcuity’s gedatolisib beats Novartis drug in Phase III test - The Pharma Letter
CELC Stock Jumps As VIKTORIA-1 Trial Hits Key Goal - timothysykes.com
CELC Stock Jumps As VIKTORIA-1 Data Fuel FDA Push - StocksToTrade
Celcuity Stock Jumps 16% as Gedatolisib Breast-Cancer Data Raise FDA Stakes - TechStock²
CELC Stock Jumps As VIKTORIA-1 Phase 3 Data Impress Wall Street - timothysykes.com
Celcuity strengthens case for ASCO-spotlighted breast cancer drug - BioPharma Dive
Celcuity CELC Soars On Strong Phase 3 Cancer Data - StocksToTrade
Celcuity rises on gedatolisib on top-line data in breast cancer - BioWorld News
Celcuity shares jump 15.5% as Phase 3 VIKTORIA-1 topline results support potential label expansion path for gedatolisib - Quiver Quantitative
Wall Street believes Celcuity could become an acquisition target – why this analyst raised their price target by a whopping 76% - MSN
CELC Stock Surges As VIKTORIA-1 Trial Hits Phase 3 Milestone - timothysykes.com
Celcuity upgraded by H.C. Wainwright with a new price target - Quantisnow
Citizens raises Celcuity stock price target on Phase 3 trial win By Investing.com - Investing.com South Africa
Citizens raises Celcuity stock price target on Phase 3 trial win - Investing.com
Celcuity’s breast cancer win; Odyssey plans $205M IPO - Endpoints News
Needham raises Celcuity stock price target to $157 on trial data - Investing.com UK
Celcuity Stock Soars 14% to $143 on Positive Phase 3 Breast Cancer Trial Data - International Business Times Australia
Needham raises Celcuity stock price target to $157 on trial data By Investing.com - Investing.com South Africa
Guggenheim raises Celcuity stock price target on trial success By Investing.com - Investing.com Canada
Guggenheim raises Celcuity stock price target on trial success - Investing.com
Stifel raises Celcuity stock price target on trial data strength By Investing.com - Investing.com Australia
Celcuity upgraded to Buy from Neutral at H.C. Wainwright - TipRanks
Stifel raises Celcuity stock price target on trial data strength - Investing.com
Celcuity Shares Climb on Positive Breast-Cancer Drug Trial Results - marketscreener.com
Celcuity price target raised to $157 from $122 at Needham - TipRanks
This Airbnb Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday - Benzinga
Wall Street Believes Celcuity Could Become An Acquisition Target – Why This Analyst Raised Their Price Target By A Whopping 76% - Stocktwits
Why Is Celcuity Stock Rallying Today? - Benzinga
As FDA decision nears, Celcuity posts win in PIK3CA-mutant breast cancer - FirstWord Pharma
Why Celcuity’s Hot Cancer Drug Stock Is Sinking - TipRanks
CELC stock jumps after hours on positive breast cancer trial data - MSN
Celcuity Stock Surges on Breakthrough Trial Results - TipRanks
Celcuity’s Gedatolisib Achieves Phase 3 Success in PIK3CA-Mutant HR+/HER2- Advanced Breast Cancer, Meeting Primary Endpoint in VIKTORIA-1 Trial 1 - Minichart
LifeSci Capital Maintains Celcuity(CELC.US) With Buy Rating, Maintains Target Price $165 - Moomoo
CELC Stock Jumps After Hours On Positive Breast Cancer Trial Data - Stocktwits
Jennison Associates LLC Purchases Shares of 229,704 Celcuity, Inc. $CELC - MarketBeat
LifeSci Capital Maintains Celcuity(CELC.US) With Buy Rating, Raises Target Price to $165 - Moomoo
Celcuity Reports Positive Phase 3 Results for Gedatolisib - TipRanks
Why Celcuity Shares Are Dropping After Big Trial Win - TipRanks
Celcuity reports positive phase 3 trial results for gedatolisib By Investing.com - Investing.com Nigeria
Celcuity announced that its Phase III Viktoria-1 clinical trial has successfully achieved the primary endpoint in the Pik3CA mutant patient cohort. - Bitget
Celcuity's Phase 3 VIKTORIA-1 Trial Achieves Primary Endpoint With Clinically Meaningful Improvement in Progression-Free Survival in PIK3CA Mutant Cohort - The Manila Times
Celcuity reports positive phase 3 trial results for gedatolisib - Investing.com
Celcuity's Phase 3 VIKTORIA-1 Trial Achieves Primary Endpoint With Clinically Meaningful ... - Caledonian Record
Celcuity's Phase 3 VIKTORIA-1 Trial Achieves Primary - GlobeNewswire
Biotech Stocks To Follow TodayMay 1st - MarketBeat
Celcuity (CELC) Is Up 6.9% After FDA Grants Priority Review For Gedatolisib And Debt FinancingHas The Bull Case Changed? - simplywall.st
CELC.O Technical Analysis & Stock Price Forecast - Intellectia AI
Celcuity Inc Azioni (CELC) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.14%
0.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):